Sanofi's Consumer Health Q2 Results Ride Emerging Markets Boost
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
French pharma's worldwide OTC drug and other consumer health product sales grow 4.1% to $1.3bn led by more than 10% growth in its emerging markets, but US sales fell nearly 6% partly due to market-share incursion by private label OTCs.
You may also be interested in...
Contamination In Common OTC Antacid Adds To FDA's API Impurity Concerns
FDA assessing contamination of Rx and OTC H2 blocker ranitidine to determine steps it should take. The contaminant, NDMA, is dangerous when consumed in large quantities, but has been found in H2 blockers at levels that don't pose a risk, FDA says.
Sanofi Lawsuit Delays OTC Nasacort Generic Competition
Sanofi says with Nasacort Allergy 24HR available at retailers nationwide and online, the firm withdrew its litigation against FDA, which appears to have slowed development of private-label equivalents.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.